Q-omics provides the consensus-scored TTTY22 profile across patient tissues and cancer cell-line models. TTTY22 expression is associated with patient survival in 6 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TTTY22 is differentially expressed in 1, with the highest sampling consensus in HNSC. Additionally, TTTY22 RNA expression shows 3,251 significant gene co-expression associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, HNSC, and STAD as cancer lineages where TTTY22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTTY22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTTY22 survival associations across molecular data types. TTTY22 RNA expression shows survival associations in the most cancer types (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTTY22 RNA expression–survival associations across cancer types. High TTTY22 expression shows unfavorable associations in KIRC, UCEC, BLCA, LUSC, SKCM and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TTTY22 RNA expression.
This table summarizes TTTY22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TTTY22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTTY22 shows lower tumor expression in HNSC. The HNSC box plot shows higher TTTY22 RNA expression in normal versus tumor tissue (log2 FC = −0.084, t-test p = .013).
This table shows molecular features associated with TTTY22 in patient tissues and cancer cell lines. In patient samples, TTTY22 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
